Viral Vectors and Plasmid DNA Manufacturing Market Research Report Information By Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Disease Type (Cancer, Genetic Disorder, and Infectious Disease), By Applications (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, and Research), By Workflow (Upstream Processing and Downstream Processing), By End User (Pharmaceutical and Biopharmaceutical Companies, and Research Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Foreca

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Demand and Supply

5.3.3. Regional Impact

5.3.4. Impact on R&D

6. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BY VECTOR TYPE

6.1. Overview

6.2. Plasmid DNA

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

6.3. Viral Vector

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

6.4. Non-Viral Vector

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

7. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE

7.1. Overview

7.2. Upstream Processing

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

7.3. Downstream Processing

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

8.1. Overview

8.2. Antisense & RNAi Therapy

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8.3. Gene Therapy

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8.4. Cell Therapy

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8.5. Vaccinology

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

8.6. Research

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

9. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE

9.1. Overview

9.2. Cancer

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

9.3. Genetic Disorders

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

9.4. Infectious Diseases

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

9.5. Others

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

10. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER

10.1. Overview

10.2. Pharmaceutical and Biopharmaceutical Companies

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

10.3. Research Institutes

Market Estimates & Forecast, by Region, 2023–2030

Market Estimates & Forecast, by Country, 2023–2030

11. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BY REGION

11.1. Overview

11.2. North America

11.2.1. US

11.2.2. Canada

11.3. Europe

11.3.1. Germany

11.3.2. France

11.3.3. Italy

11.3.4. Spain

11.3.5. UK

11.3.6. Rest of Europe

11.4. Asia-Pacific

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. Australia

11.4.5. South Korea

11.4.6. Rest of Asia-Pacific

11.5. Rest of the World

11.5.1. Middle East

11.5.2. Africa

11.5.3. Latin America

12. COMPANY LANDSCAPE

12.1. Overview

12.2. Competitive Analysis

12.3. Market Share Analysis

12.4. Major Growth Strategy in the Global Viral Vectors And Plasmid DNA ManufacturingMarket

12.5. Competitive Benchmarking

12.6. Leading Players in Terms of Number of Developments in the Global Viral Vectors And Plasmid Dna ManufacturingMarket

12.7. Key developments and Growth Strategies

12.7.1. New Product Launch/Service Deployment

12.7.2. Merger &Acquisitions

12.7.3. Joint Ventures

12.8. Major Players Financial Matrix

12.8.1. Sales & Operating Inc.ome, 2020

12.8.2. Major Players R&D Expenditure, 2020

13. COMPANY PROFILES

13.1. Cognate BioservicesInc.

13.1.1. Company Overview

13.1.2. Products Offered

13.1.3. Financial Overview

13.1.4. Key Developments

13.1.5. SWOT Analysis

13.1.6. Key Strategies

13.2. Catalent Pharma Solutions

13.2.1. Company Overview

13.2.2. Products Offered

13.2.3. Financial Overview

13.2.4. Key Developments

13.2.5. SWOT Analysis

13.2.6. Key Strategies

13.3. Fujifilm Holdings Corporation

13.3.1. Company Overview

13.3.2. Products Offered

13.3.3. Financial Overview

13.3.4. Key Developments

13.3.5. SWOT Analysis

13.3.6. Key Strategies

13.4. Johnson & Johnson

13.4.1. Company Overview

13.4.2. Products Offered

13.4.3. Financial Overview

13.4.4. Key Developments

13.4.5. SWOT Analysis

13.4.6. Key Strategies

13.5. Sanofi Corporation

13.5.1. Company Overview

13.5.2. Products Offered

13.5.3. Financial Overview

13.5.4. Key Developments

13.5.5. SWOT Analysis

13.5.6. Key Strategies

13.6. F-Hoffman LA Roche Ltd

13.6.1. Company Overview

13.6.2. Products Offered

13.6.3. Financial Overview

13.6.4. Key Developments

13.6.5. SWOT Analysis

13.6.6. Key Strategies

13.7. 4D Molecular Therapeutics

13.7.1. Company Overview

13.7.2. Products Offered

13.7.3. Financial Overview

13.7.4. Key Developments

13.7.5. SWOT Analysis

13.7.6. Key Strategies

13.8. Sirion Biotech GmbH

13.8.1. Company Overview

13.8.2. Products Offered

13.8.3. Financial Overview

13.8.4. Key Developments

13.8.5. SWOT Analysis

13.8.6. Key Strategies

13.9. Voyager Therapeutics

13.9.1. Company Overview

13.9.2. Products Offered

13.9.3. Financial Overview

13.9.4. Key Developments

13.9.5. SWOT Analysis

13.9.6. Key Strategies

13.10. Thermo Fisher Scientific

13.10.1. Company Overview

13.10.2. Products Offered

13.10.3. Financial Overview

13.10.4. Key Developments

13.10.5. SWOT Analysis

13.10.6. Key Strategies

13.11. Gene Therapy Catapult

13.11.1. Company Overview

13.11.2. Products Offered

13.11.3. Financial Overview

13.11.4. Key Developments

13.11.5. SWOT Analysis

13.11.6. Key Strategies

13.12. Uniqure

13.12.1. Company Overview

13.12.2. Products Offered

13.12.3. Financial Overview

13.12.4. Key Developments

13.12.5. SWOT Analysis

13.12.6. Key Strategies

13.13. Mass Biologics

13.13.1. Company Overview

13.13.2. Products Offered

13.13.3. Financial Overview

13.13.4. Key Developments

13.13.5. SWOT Analysis

13.13.6. Key Strategies

13.14. Renova Therapeutics

13.14.1. Company Overview

13.14.2. Products Offered

13.14.3. Financial Overview

13.14.4. Key Developments

13.14.5. SWOT Analysis

13.14.6. Key Strategies

13.15. Shenzhen SiBionoGeneTech Co., Ltd

13.15.1. Company Overview

13.15.2. Products Offered

13.15.3. Financial Overview

13.15.4. Key Developments

13.15.5. SWOT Analysis

13.15.6. Key Strategies

14. APPENDIX

14.1. References

14.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET SYNOPSIS, 2023–2030

TABLE 2 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET ESTIMATES &FORECAST, 2023–2030(USD MILLION)

TABLE 3 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BYVECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 4 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 5 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 6 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 7 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 8 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 9 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 10 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 11 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 12 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 13 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 14 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 15 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 16 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 17 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 18 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 19 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 20 CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 21 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 22 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 23 EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 24 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 25 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 26 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 27 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 28 GERMANY: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 29 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 30 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 31 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 32 GERMANYVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 33 UK: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 34 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 35 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 36 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 37 UKVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 38 FRANCE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 39 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 40 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 41 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 42 FRANCEVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 43 ITALY: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 44 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 45 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 46 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 47 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 48 SPAIN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 49 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 50 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 51 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 52 SPAINVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 53 REST OF EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 54 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 55 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 56 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 57 REST OF EUROPEVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 58 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 61 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 63 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 64 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 65 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 66 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 67 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 68 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 69 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 70 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 71 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 72 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 73 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 74 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 75 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 76 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 77 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 78 SOUTH KOREAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 79 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 80 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 81 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 82 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 83 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 84 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 85 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 86 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 87 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 88 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 89 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 90 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 91 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 92 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 93 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 94 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 95 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 96 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 97 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 98 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 99 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 100 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 101 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER TYPE, 2023–2030 (USD MILLION)

TABLE 102 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 103 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 104 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 105 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 106 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 107 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 108 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 109 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 110 AFRICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 111 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

TABLE 112 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2023–2030 (USD MILLION)

TABLE 113 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2023–2030 (USD MILLION)

TABLE 114 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)

TABLE 115 LATIN AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 116 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023–2030 (USD MILLION

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET

FIGURE 4 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET SHARE, BY VECTOR TYPE, 2020 (%)

FIGURE 5 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY APPLICATION, 2020 (%)

FIGURE 6 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 12 COGNATE BIOSERVICES, INC.: KEY FINANCIALS

FIGURE 13 COGNATE BIOSERVICES, INC.: SEGMENTAL REVENUE

FIGURE 14 COGNATE BIOSERVICES, INC.: REGIONAL REVENUE

FIGURE 15 CATALENT PHARMA SOLUTIONS: KEY FINANCIALS

FIGURE 16 CATALENT PHARMA SOLUTIONS: SEGMENTAL REVENUE

FIGURE 17 CATALENT PHARMA SOLUTIONS: REGIONAL REVENUE

FIGURE 18 FUJIFILM HOLDINGS CORPORATION: KEY FINANCIALS

FIGURE 19 FUJIFILM HOLDINGS CORPORATION: SEGMENTAL REVENUE

FIGURE 20 FUJIFILM HOLDINGS CORPORATION: REGIONAL REVENUE

FIGURE 21 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 22 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 23 JOHNSON & JOHNSON: REGIONAL REVENUE

FIGURE 24 SANOFI CORPORATION: KEY FINANCIALS

FIGURE 25 SANOFI CORPORATION: SEGMENTAL REVENUE

FIGURE 26 SANOFI CORPORATION: REGIONAL REVENUE

FIGURE 27 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 28 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 29 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 30 4D MOLECULAR THERAPEUTICS: KEY FINANCIALS

FIGURE 31 4D MOLECULAR THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 32 4D MOLECULAR THERAPEUTICS: REGIONAL REVENUE

FIGURE 33 SIRION BIOTECH GMBH: KEY FINANCIALS

FIGURE 34 SIRION BIOTECH GMBH: SEGMENTAL REVENUE

FIGURE 35 SIRION BIOTECH GMBH: REGIONAL REVENUE

FIGURE 36 VOYAGER THERAPEUTICS: KEY FINANCIALS

FIGURE 37 VOYAGER THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 38 VOYAGER THERAPEUTICS: REGIONAL REVENUE

FIGURE 39 THERMO FISHER SCIENTIFIC, INC.: KEY FINANCIALS

FIGURE 40 THERMO FISHER SCIENTIFIC, INC.: SEGMENTAL REVENUE

FIGURE 41 THERMO FISHER SCIENTIFIC, INC.: REGIONAL REVENUE

FIGURE 42 GENE THERAPY CATAPULT: KEY FINANCIALS

FIGURE 43 GENE THERAPY CATAPULT: SEGMENTAL REVENUE

FIGURE 44 GENE THERAPY CATAPULT: REGIONAL REVENUE

FIGURE 45 UNIQURE: KEY FINANCIALS

FIGURE 46 UNIQURE: SEGMENTAL REVENUE

FIGURE 47 UNIQURE: REGIONAL REVENUE

FIGURE 48 MASSBIOLOGICS: KEY FINANCIALS

FIGURE 49 MASSBIOLOGICSSEGMENTAL REVENUE

FIGURE 50 MASSBIOLOGICS: REGIONAL REVENUE

FIGURE 51 RENOVA THERAPEUTICS: KEY FINANCIALS

FIGURE 52 RENOVA THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 53 RENOVA THERAPEUTICS: REGIONAL REVENUE

FIGURE 54 SHENZHEN SIBIONO GENETECH CO., LTD: KEY FINANCIALS

FIGURE 55 SHENZHEN SIBIONO GENETECH CO., LTD: SEGMENTAL REVENUE

FIGURE 56 SHENZHEN SIBIONO GENETECH CO., LTD: REGIONAL REVENUE